Regencell Bioscience Holdings Ltd (RGC) stock
RGCNasdaqMedicinal Chemicals & Botanical Products
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.36−0.33 (-7.04%)
Close on Nov 19, 2026Market cap $2.16BP/E –Yield –
Regencell Bioscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2026 it was -$7.70M. The highest annual figure on record is -$390.99K in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$7.70M | – |
| FY2025 | Jun 30, 2025 | -$3.11M | – |
| FY2024 | Jun 30, 2024 | -$4.00M | – |
| FY2023 | Jun 30, 2023 | -$4.96M | – |
| FY2022 | Jun 30, 2022 | -$5.27M | – |
| FY2021 | Jun 30, 2021 | -$767.31K | – |
| FY2020 | Jun 30, 2020 | -$726.57K | – |
| FY2019 | Jun 30, 2019 | -$390.99K | – |
See a number that looks wrong?